Unweighted % | Weighted %* | ||
---|---|---|---|
Sociodemographic characteristics | |||
Jurisdiction | RoI | 70% | 77% |
NI | 30% | 23% | |
Age at diagnosis (years) | ≤59 | 24% | 22% |
60–69 | 49% | 44% | |
≥70 | 24% | 34% | |
Survivorship phase | Short-term | 48% | 42% |
Long-tem | 32% | 43% | |
Very long-term | 20% | 16% | |
Patient-reported outcomes | |||
EQ-5D-5L | Utility score | 0.82 | 0.82 |
Mobility | 1.6 | 1.6 | |
Self-care | 1.2 | 1.2 | |
Usual activities | 1.6 | 1.7 | |
Pain/discomfort | 1.6 | 1.6 | |
Anxiety/depression | 1.4 | 1.4 | |
EORTC QLQ-C30 | GHS | 71.53 | 71.15 |
Functioning subscales | Physical functioning | 82.16 | 81.54 |
Role functioning | 80.91 | 80.57 | |
Emotional functioning | 83.51 | 83.66 | |
Cognitive functioning | 82.27 | 82.24 | |
Social functioning | 82.16 | 82.48 | |
Symptoms subscales | Fatigue | 23.96 | 23.92 |
Nausea and vomiting | 4.19 | 4.06 | |
Pain | 15.39 | 15.20 | |
Dyspnoea | 16.87 | 16.82 | |
Insomnia | 23.57 | 23.29 | |
Appetite loss | 7.00 | 7.00 | |
Constipation | 13.16 | 13.37 | |
Diarrhoea | 9.69 | 9.57 | |
Financial difficulties | 11.48 | 11.13 | |
EORTC QLQ-PR25 | Urinary symptoms | 19.76 | 19.47 |
Urinary bother | 15.57 | 14.79 | |
Bowel symptoms | 7.29 | 7.10 | |
Treatment symptoms | 10.62 | 10.17 | |
Sexual activity | 67.80 | 68.61 | |
Sexual functioning | 48.40 | 48.08 | |
DASS-21 | Depression | 16.5% | 16.3% |
Anxiety | 16.4% | 16.1% | |
Distress | 10.6% | 10.4% |
Depression, anxiety and distress were defined as men scoring ≥10, ≥8 and ≥15, on the respective subscales.21
*Using survey methods, weights were computed based on time since diagnosis, age at diagnosis and jurisdiction.
DASS, 21-question Depression, Anxiety and Stress (Di)Stress Scale; GHS, Global Health Status; NI, Northern Ireland; PiCTure, Prostate Cancer Treatment, your experience; RoI, Republic of Ireland.